Tiffany A Traina, Kathy Miller, Denise A Yardley, Janice Eakle, Lee S Schwartzberg, Joyce O'Shaughnessy, William Gradishar, Peter Schmid, Eric Winer, Catherine Kelly, Rita Nanda, Ayca Gucalp, Ahmad Awada, Laura Garcia-Estevez, Maureen E Trudeau, Joyce Steinberg, Hirdesh Uppal, Iulia Cristina Tudor, Amy Peterson, Javier Cortes
Purpose Studies suggest that a subset of patients with triple-negative breast cancer (TNBC) have tumors that express the androgen receptor (AR) and may benefit from an AR inhibitor. This phase II study evaluated the antitumor activity and safety of enzalutamide in patients with locally advanced or metastatic AR-positive TNBC. Patients and Methods Tumors were tested for AR with an immunohistochemistry assay optimized for breast cancer; nuclear AR staining > 0% was considered positive. Patients received enzalutamide 160 mg once per day until disease progression...
March 20, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology